16:55 , Jan 12, 2018 |  BC Week In Review  |  Company News

Exelixis, StemSynergy in CSNK1A activator deal

Exelixis Inc. (NASDAQ:EXEL) and StemSynergy Therapeutics Inc. (Miami, Fla.) partnered to discover and develop compounds targeting casein kinase 1 alpha (CSNK1A; CKI-alpha) to treat cancer. The partners will conduct preclinical and clinical studies of compounds from...
21:05 , Jul 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample, in vitro, cell culture and mouse studies identified a benzamide-based CSNK1A activator that could help treat Wnt signaling-driven colorectal cancer. In colorectal cancer patients, low tumor levels of CSNK1A were associated...
07:00 , Aug 4, 2016 |  BC Innovations  |  Targets & Mechanisms

Cereblon ambition

Most anti-cancer strategies aim to block overactive proteins by directly inhibiting their activity, but a growing number of companies are developing ways to tag the proteins for destruction by recruiting the enzymes that shuttle them...
07:00 , May 16, 2016 |  BC Week In Review  |  Company News

Hebrew University of Jerusalem, BioTheryX deal

The university’s Yissum Research Development Co. and BioTheryX partnered to develop and commercialize casein kinase 1 alpha ( CSNK1A; CKI-alpha) inhibitors to treat hematologic and solid malignancies. The collaboration will initially focus on...
07:00 , Oct 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Myelodysplastic syndrome (MDS) Casein kinase 1 (CSNK1; CKI) In vitro and mouse studies suggest inhibiting CSNK1 could...
07:00 , Aug 28, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Casein kinase 1a (CSNK1A; CKI-a); sonic hedgehog homolog (SHH) Mouse and cell culture studies suggest...
07:00 , May 15, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke; nerve damage Casein kinase 1 (CSNK1; CKI); RE1-silencing transcription factor (REST; NRSF) In vitro and rat...
07:00 , May 12, 2014 |  BioCentury  |  Emerging Company Profile

Pharmasum: Down with AD

Pharmasum Therapeutics A/S is looking to treat the large number of Down syndrome patients who develop Alzheimer's disease-like pathology. The company's first-in-class inhibitor could slow cognitive decline in Down syndrome by targeting a kinase that...
07:00 , Apr 17, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML) Casein kinase 1α (CSNK1A; CKI-α) Mouse and cell culture studies suggest inhibiting CKI-a...
07:00 , Oct 3, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer b-Catenin (CTNNB1); B cell lymphoma 2 (BCL-2; BCL2); AXIN1; casein kinase 1a (CSNK1A1; CKI-a) In...